Frequency of spontaneous resistance to peptide deformylase inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4644-4652

  Min, Sharon ^a   Ingraham, Karen ^a   Huang, Jianzhong ^a   McCloskey, Lynn ^a   Rilling, Sarah ^a,c   Windau, Anne ^b   Pizzollo, Jason ^a,d   Butler, Deborah ^a   Aubart, Kelly ^a   Miller, Linda A ^a   Zalacain, Magdalena ^a,e   Holmes, David J ^a   O'Dwyer, Karen ^a  

^a GLAXOSMITHKLINE   (United States)

^b Laboratory Specialists Inc   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e Zala Drug Discovery Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANOPEPDEN; AMIDASE; ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS; HYDROXAMIC ACID; PEPTIDE DEFORMYLASE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; LIMIT OF DETECTION; LOSS OF FUNCTION MUTATION; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TIME-DEPENDENT INHIBITION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HAEMOPHILUS INFECTIONS; HUMAN; MICROBIAL SENSITIVITY TEST; PNEUMOCOCCAL INFECTIONS; PROCEDURES; STAPHYLOCOCCAL INFECTIONS;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; HYDROXAMIC ACIDS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 84940193658     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00484-15     Document Type: Article

References (33)

1. Adams JM. 1968. On the release of the formyl group from nascent protein. J Mol Biol 33:571-589. http://dx.doi.org/10.1016/0022-2836(68)90307-0.
2. Ball LA, Kaesberg P. 1973. Cleavage of the N-terminal formylmethionine residue from a bacteriophage coat protein in vitro. J Mol Biol 79:531-537. http://dx.doi.org/10.1016/0022-2836(73)90404-X.
3. Livingston DM, Leder P. 1969. Deformylation and protein biosynthesis. Biochemistry 8:435-443. http://dx.doi.org/10.1021/bi00829a059.
4. Aubart K, Zalacain M. 2006. Peptide deformylase inhibitors. Prog Med Chem 44:109-143. http://dx.doi.org/10.1016/S0079-6468(05)44403-3.
5. Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K. 2004. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother 53:664-668. http://dx.doi.org/10.1093/jac/dkh129.
6. Fritsche TR, Sader HS, Cleeland R, Jones RN. 2005. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob Agents Chemother 49:1468-1476. http://dx.doi.org/10.1128/AAC.49.4.1468-1476.2005.
7. O'Dwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D, Aubart K, Zalacain M, Butler D. 2013. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob Agents Chemother 57:2333-2342. http://dx.doi.org/10.1128/AAC.02566-12.
8. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 57:2005-2009. http://dx.doi.org/10.1128/AAC.01779-12.
9. Naderer OJ, Jones LS, Zhu J, Kurtinecz M, Dumont E. 2013. Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor. J Clin Pharmacol 53:1168-1176. http://dx.doi.org/10.1002/jcph.150.
10. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study. J Antimicrob Chemother 68:1901-1909. http://dx.doi.org/10.1093/jac/dkt097.
11. Corey R, Naderer OJ, O'Riordan WD, Dumont E, Jones LS, Kurtinecz M, Zhu JZ. 2014. Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 58:6518-6527. http://dx.doi.org/10.1128/AAC.03360-14.
12. Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen D, Yuan Z, White R, Trias J. 2000. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother 44:1825-1831. http://dx.doi.org/10.1128/AAC.44.7.1825-1831.2000.
13. Clements JM, Beckett RP, Brown A, Catlin G, Lobell M, Palan S, Thomas W, Whittaker M, Wood S, Salama S, Baker PJ, Rodgers HF, Barynin V, Rice DW, Hunter MG. 2001. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 45:563-570. http://dx.doi.org/10.1128/AAC.45.2.563-570.2001.
14. Duroc Y, Giglione C, Meinnel T. 2009. Mutations in three distinct loci cause resistance to peptide deformylase inhibitors in Bacillus subtilis. Antimicrob Agents Chemother 53:1673-1678. http://dx.doi.org/10.1128/AAC.01340-08.
15. Newton DT, Creuzenet C, Mangroo D. 1999. Formylation is not essential for initiation of protein synthesis in all eubacteria. J Biol Chem 274:22143-22146. http://dx.doi.org/10.1074/jbc.274.32.22143.
16. Nilsson AI, Zorzet A, Kanth A, Dahlstrom S, Berg OG, Andersson DI. 2006. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc Natl Acad Sci U S A103:6976-6981. http://dx.doi.org/10.1073/pnas.0602171103.
17. Apfel CM, Locher H, Evers S, Takacs B, Hubschwerlen C, Pirson W, Page MG, Keck W. 2001. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob Agents Chemother 45:1058-1064. http://dx.doi.org/10.1128/AAC.45.4.1058-1064.2001.
18. Guillon JM, Mechulam Y, Schmitter JM, Blanquet S, Fayat G. 1992. Disruption of the gene for fMet formyltransferase severely impairs growth of Escherichia coli. J Bacteriol 174:4294-4301.
19. Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR. 2006. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J Antimicrob Chemother 57:914-923. http://dx.doi.org/10.1093/jac/dkl093.
20. Lewandowski T, Huang J, Fan F, Rogers S, Gentry D, Holland R, Demarsh P, Aubart K, Zalacain M. 2013. Staphylococcus aureus formylmethionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity. Antimicrob Agents Chemother 57:2929-2936. http://dx.doi.org/10.1128/AAC.00162-13.
21. Margolis P, Hackbarth C, Lopez S, Maniar M, Wang W, Yuan Z, White R, Trias J. 2001. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob Agents Chemother 45:2432-2435. http://dx.doi.org/10.1128/AAC.45.9.2432-2435.2001.
22. Kosowska-Shick K, Credito KL, Pankuch GA, DeWasse B, McGhee P, Appelbaum PC. 2007. Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. Antimicrob Agents Chemother 51:770-773. http://dx.doi.org/10.1128/AAC.01150-06.
23. Dean CR, Narayan S, Richards J, Daigle DM, Esterow S, Leeds JA, Kamp H, Puyang X, Wiedmann B, Mueller D, Voshol H, van Oostrum J, Wall D, Koehn J, Dzink-Fox J, Ryder NS. 2007. Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number. Antimicrob Agents Chemother 51:1004-1010. http://dx.doi.org/10.1128/AAC.01103-06.
24. Dean CR, Narayan S, Daigle DM, Dzink-Fox JL, Puyang X, Bracken KR, Dean KE, Weidmann B, Yuan Z, Jain R, Ryder NS. 2005. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrob Agents Chemother 49:3129-3135. http://dx.doi.org/10.1128/AAC.49.8.3129-3135.2005.
25. th ed. Document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Met formyltransferase: comparison with glycinamide ribonucleotide formyltransferase. EMBO J 15:4749-4758.
27. Baldwin ET, Harris MS, Yem AW, Wolfe CL, Vosters AF, Curry KA, Murray RW, Bock JH, Marshall VP, Cialdella JI, Merchant MH, Choi G, Deibel MR, Jr. 2002. Crystal structure of type II peptide deformylase from Staphylococcus aureus. J Biol Chem 277:31163-31171. http://dx.doi.org/10.1074/jbc.M202750200.
28. Meinnel T, Lazennec C, Villoing S, Blanquet S. 1997. Structure-function relationships within the peptide deformylase family: evidence for a conserved architecture of the active site involving three conserved motifs and a metal ion. J Mol Biol 267:749-761. http://dx.doi.org/10.1006/jmbi.1997.0904.
29. Apfel CM, Evers S, Hubschwerlen C, Pirson W, Page MG, Keck W. 2001. Peptide deformylase as an antibacterial drug target: assays for detection of its inhibition in Escherichia coli cell homogenates and intact cells. Antimicrob Agents Chemother 45:1053-1057. http://dx.doi.org/10.1128/AAC.45.4.1053-1057.2001.
30. Meinnel T, Lazennec C, Blanquet S. 1995. Mapping of the active site zinc ligands of peptide deformylase. J Mol Biol 254:175-183. http://dx.doi.org/10.1006/jmbi.1995.0609.
31. Chan MK, Gong W, Rajagopalan PT, Hao B, Tsai CM, Pei D. 1997. Crystal structure of the Escherichia coli peptide deformylase. Biochemistry 36:13904-13909. http://dx.doi.org/10.1021/bi9711543.
32. Van Aller GS, Nandigama R, Petit CM, DeWolf WE, Jr, Quinn CJ, Aubart KM, Zalacain M, Christensen SB, Copeland RA, Lai Z. 2005. Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin. Biochemistry 44:253-260. http://dx.doi.org/10.1021/bi048632b.
33. Totoritis R, Duraiswami C, Taylor AN, Kerrigan JJ, Campobasso N, Smith KJ, Ward P, King BW, Murrayz-Thompson M, Jones AD, Van Aller GS, Aubart KM, Zalacain M, Thrall SH, Meek TD, Schwartz B. 2011. Understanding the origins of time-dependent inhibition by polypeptide deformylase inhibitors. Biochemistry 50:6642-6654. http://dx.doi.org/10.1021/bi200655g.